Molecularly targeted drugs against EGFR mainly include tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, and monoclonal antibodies such as cetuximab and panitumumab; however, many clinical trials have confirmed that ESCC do not respond to these drugs [37,38,39,40]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.